2023
DOI: 10.1002/btpr.3378
|View full text |Cite
|
Sign up to set email alerts
|

Current challenges and recent advances on the path towards continuous biomanufacturing

Abstract: Continuous biopharmaceutical manufacturing is currently a field of intense research due to its potential to make the entire production process more optimal for the modern, ever‐evolving biopharmaceutical market. Compared to traditional batch manufacturing, continuous bioprocessing is more efficient, adjustable, and sustainable and has reduced capital costs. However, despite its clear advantages, continuous bioprocessing is yet to be widely adopted in commercial manufacturing. This article provides an overview … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 222 publications
(548 reference statements)
0
1
0
Order By: Relevance
“…It is important to note that should these changes be implemented after confirmatory trials or after approval of the drug; then a comparability exercise would be required, including physiochemical and biological in vitro studies, as well as potentially clinical pharmacokinetic and pharmacodynamic comparability studies (European Medicines Agency, 2007;Federal Food and Drug Administration,18, 2018). For implementing process intensification into an already existing commercial product, this may be the biggest hurdle to overcome (Drobnjakovic et al, 2023;Nasr et al, 2017).…”
Section: Levelmentioning
confidence: 99%
“…It is important to note that should these changes be implemented after confirmatory trials or after approval of the drug; then a comparability exercise would be required, including physiochemical and biological in vitro studies, as well as potentially clinical pharmacokinetic and pharmacodynamic comparability studies (European Medicines Agency, 2007;Federal Food and Drug Administration,18, 2018). For implementing process intensification into an already existing commercial product, this may be the biggest hurdle to overcome (Drobnjakovic et al, 2023;Nasr et al, 2017).…”
Section: Levelmentioning
confidence: 99%